Criterium, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.criteriuminc.com
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01660750
- Locations
- ๐บ๐ธ
Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธUniversity of Massachusettes Memorial, Worcester, Massachusetts, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01464034
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธFred Hutchinson Cancer Research Center, Seattle, Washington, United States
๐บ๐ธThe John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath